These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16088172)

  • 1. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin.
    Kavak A; Akcan Y; Korkmaz U
    Dermatology; 2005; 211(2):171-2. PubMed ID: 16088172
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lingual hyperpigmentation in a patient with chronic infection].
    López Peláez MV; González Díaz P; Téllez Molina MJ; Vergas García J
    Enferm Infecc Microbiol Clin; 2013 Apr; 31(4):264-5. PubMed ID: 23260387
    [No Abstract]   [Full Text] [Related]  

  • 3. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New triple therapy in chronic hepatitis C. Increased patient chances].
    Stiefelhagen P
    MMW Fortschr Med; 2011 Sep; 153(39):20. PubMed ID: 21991830
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
    Alberti AB; Belli LS; Airoldi A; de Carlis L; Rondinara G; Minola E; Vangeli M; Cernuschi A; D'Amico M; Forti D; Pinzello G
    Liver Transpl; 2001 Oct; 7(10):870-6. PubMed ID: 11679985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin.
    Ancel D; Amiot X; Chaslin-Ferbus D; Hagege I; Garioud A; Girot R; Pol S; Grange JD
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):726-9. PubMed ID: 19404206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
    van Leeuwen DJ; Yee LJ; Langner RG
    Am J Gastroenterol; 2002 Feb; 97(2):497-8. PubMed ID: 11866304
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chronic hepatitis C: what to do if the first treatment failed?].
    Asselah T
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B50-9. PubMed ID: 12180309
    [No Abstract]   [Full Text] [Related]  

  • 9. Tongue hyperpigmentation during interferon-alpha and ribavirin therapy.
    Aguayo-Leiva I; Pérez B; Salguero I; Jaén P
    Eur J Dermatol; 2009; 19(3):291-2. PubMed ID: 19286489
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
    Sidhu-Malik NK; Kaplan AL
    J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effects of interferon on chronic hepatitis C from the aspect of dosage and method of administration].
    Fukuda A
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):493-6. PubMed ID: 15359848
    [No Abstract]   [Full Text] [Related]  

  • 12. A fatal case of phlegmonous colitis in chronic hepatitis C receiving combination interferon and ribavirin therapy.
    Pang SH; de Silva K; Napoli J; Jones BE
    Intern Med J; 2009 Jul; 39(7):481-4. PubMed ID: 19664159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The adherence in the treatment of chronic hepatitis C].
    Pawłowska M; Halota W
    Pol Merkur Lekarski; 2005 Apr; 18(106):469-72. PubMed ID: 16161937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C.
    Jessner W; Der-Petrossian M; Christiansen L; Maier H; Steindl-Munda P; Gangl A; Ferenci P
    Hepatology; 2002 Nov; 36(5):1301-2. PubMed ID: 12395349
    [No Abstract]   [Full Text] [Related]  

  • 15. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS
    Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Sho Y; Fujisaki K; Sakashita H; Yamaguchi K; Tahara K; Kubozono O; Ido A; Tsubouchi H
    J Gastroenterol; 2004 Dec; 39(12):1202-4. PubMed ID: 15622486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.
    Abdelmalek MF; Liu C; Valentine JF
    Am J Gastroenterol; 2007 Jun; 102(6):1333-4. PubMed ID: 17531027
    [No Abstract]   [Full Text] [Related]  

  • 18. Depression in chronic hepatitis: the virus, the drug, or the ethnic background?
    Ferenci P; Staufer K
    Liver Int; 2008 Apr; 28(4):429-31. PubMed ID: 18339069
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
    Iyoda K; Kato M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):502-5. PubMed ID: 15359850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.